A phase I study of the AKT inhibitor MK-2206 plus hormonal therapy in postmenopausal women with estrogen receptor positive (ER+) metastatic breast cancer (MBC).

Cynthia X Ma,Timothy J Pluard,Ben Ho Park,L Austin Doyle,Bracha Erlanger,Zhanfang Guo,Matthew J Ellis,Michael Naughton,Albert C Lockhart,Feng Gao,Allison N Creekmore,Steven Sorscher,Farrokh Dehdashti

doi:10.1200/jco.2014.32.15_suppl.553

A phase I study of the AKT inhibitor MK-2206 plus hormonal therapy in postmenopausal women with estrogen receptor positive (ER+) metastatic breast cancer (MBC).

Cynthia X Ma, Timothy J Pluard + Show 11 more

https://doi.org/10.1200/jco.2014.32.15_suppl.553

Copy DOI

Journal: Journal of Clinical Oncology

Publication Date: May 20, 2014

Affiliation: University of Washington, Washington University in St. Louis, Sidney Kimmel Comprehensive Cancer Center, National Cancer Institute

#Hormonal Therapy In Postmenopausal Women #Trial Of MK-2206 + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

553 Background: Inhibition of the PI3K/AKT pathway synergize with hormonal therapy for ER+ BC in preclinical studies. We conducted a phase I trial of MK-2206 plus anastrozole (A) (Phase IA and IB) ...

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Clinical Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.